

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

## Endemic means change as SARS-CoV-2 evolves

Sarah P. Otto<sup>1</sup>, Ailene MacPherson<sup>2</sup>, & Caroline Colijn<sup>2</sup>


1. Department of Zoology & Biodiversity Research Centre, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. [otto@zoology.ubc.ca](mailto:otto@zoology.ubc.ca)
2. Department of Mathematics, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

## 19 Summary

20 COVID-19 has become endemic, with dynamics that reflect the waning of immunity and re-exposure,  
21 by contrast to the epidemic phase driven by exposure in immunologically naïve populations. Endemic  
22 does not, however, mean constant. Further evolution of SARS-CoV-2, as well as changes in behaviour  
23 and public health policy, continue to play a major role in the endemic load of disease and mortality. In  
24 this paper, we analyse evolutionary models to explore the impact that newly arising variants can have on  
25 the short-term and longer-term endemic load, characterizing how these impacts depend on the  
26 transmission and immunological properties of variants. We describe how evolutionary changes in the  
27 virus will increase the endemic load most for persistently immune-escape variants, by an intermediate  
28 amount for more transmissible variants, and least for transiently immune-escape variants. Balancing the  
29 tendency for evolution to favour variants that increase the endemic load, we explore the impact of  
30 vaccination strategies and non-pharmaceutical interventions (NPIs) that can counter these increases in  
31 the impact of disease. We end with some open questions about the future of COVID-19 as an endemic  
32 disease.

## 33 Introduction

34 Early in the global pandemic, COVID-19 levels rose and fell steeply, displaying rapid exponential  
35 growth and leading to widespread lockdowns and other public health measures to slow transmission  
36 (Ogden et al. 2022; Talic et al. 2021). The vaccination campaigns of 2021, followed by the nearly-  
37 uncontrolled Omicron waves in early 2022 (Figure 1, BA.1 and BA.2 peaks), have now led to almost  
38 100% immunological exposure in many countries. In Canada, for example, 100% of blood donors had  
39 developed antibodies to the spike protein from previous exposure to the virus by June 2023, with 80%  
40 also showing antibodies to nucleocapsid, indicating prior infection (Canadian Blood Services 2023). The  
41 number of immunologically naïve individuals that fed COVID-19 dynamics throughout the pandemic  
42 has now greatly decreased, but in its place is a continual flow of newly susceptible individuals as  
43 humoral immunity wanes. For the past year, COVID-19 levels have ebbed and flowed in response to this  
44 waning immunity, new variants, and to changing public health measures. These peaks and troughs are  
45 more subdued wavelets, compared to earlier Omicron peaks (Figure 1).



47 **FIGURE 1: COVID-19 trends across four provinces in Canada.** Major waves in early 2022  
48 were driven by the rise and spread of Omicron, whose immune-evasive properties allowed  
49 widespread infection at a time when public health measures were largely relaxed (peak in January  
50 2022: BA.1, April: BA.2, July: BA.4 & BA.5). A year later, Omicron variants have continued to  
51 spread rapidly (peak in December 2022: BQ.1; April 2023: XBB.1.5), but they no longer cause  
52 major waves in cases. PCR-confirmed cases per 100,000 individuals aged 70+ (green dots) are  
53 used to illustrate case trends, as testing practices changed dramatically over this time period but  
54 this age group remained eligible for testing. To guide the eye, a cubic spline fit ( $\lambda=3$ ) was  
55 applied (top curves in each panel), and the frequency changes of each variant under this curve were  
56 fitted by maximum likelihood using duotang (CoVaRR-Net’s CAMEO 2023). Genomic sequence  
57 data from each province were obtained from the Canadian VirusSeq Portal (VirusSeq 2023) and fit  
58 by maximum likelihood to a model of selection in two periods: first 9 months using BA.1 as a  
59 reference (left of dashed line); second 9 months using BA.4/5 as a reference (right of dashed line),  
60 grouping all clades within a family together except when a sub-clade is also mentioned (e.g., BQ.1  
61 separated from BA.5). See supplementary *Mathematica* file for scripts and duotang (CoVaRR-  
62 Net’s CAMEO 2023) for methodological details and finer resolution of lineages and time periods.

63 COVID-19 is now considered an endemic disease, being both widespread and persistent, adding to the  
64 respiratory infectious diseases with which we must routinely contend. Its now-endemic nature reflects a  
65 balance between waning immunity and on-going transmission, leading to a turnover of cases across the  
66 globe. Endemic does not mean “constant”, as new variants and behavioral shifts drive change. Endemic  
67 also does not mean “rare”, as waning and transmission rates have remained high (e.g., Figure 1). Here  
68 we explore mathematical models to improve understanding of how the ongoing evolution of SARS-  
69 CoV-2, as well as our behavioural responses, will shape endemic COVID-19 and similar diseases.

70 When most individuals in a population are susceptible (epidemic phase), any variant or behavioural  
71 measure that affects the transmission rate will have a direct effect on the number of new infections over  
72 the short term, as exposures determine the spread of disease. When a disease first appears, the  
73 reproductive number describing the number of new infections per infection,  $R_0$ , is given by the  
74 transmission rate divided by the clearance rate of the infection in the classic SIR epidemiological model  
75 (Keeling and Rohani 2011). Thus, variants that increase transmission or behavioural changes that reduce  
76 transmission directly reduce new infections and the rate of exponential growth, but these new infections  
77 have little immediate effect on the large pool of susceptible individuals. Models of this epidemic phase  
78 (e.g., (Day et al. 2020)) also typically ignore waning of immunity or the possibility that variants may  
79 evade any such immunity earlier.

80 By contrast, when a disease is endemic and most individuals have some degree of immunity, waning  
81 must be explicitly considered and modeled in a manner that allows variants to infect earlier (as in the  
82  $SIR_n$  model, with multiple recovered classes, that we consider here). Furthermore, any change in the  
83 transmission rate has a more complex effect on the number of infections in the near future, because  
84 higher transmissibility depletes the number of susceptible individuals whose immunity has waned (by  
85 “refreshing” that immunity through exposure), while lowering transmission allows susceptible  
86 individuals to accumulate.

87 Indeed, this kind of reasoning about endemic disease has been used as an argument against non-  
88 pharmaceutical measures like masking:

89 Masks “can delay transmission, they can reduce transmission, but they’re not actually effective  
90 measures at a population level,” because “exposure is essentially universal now to COVID-19.”

91 Public Health Officer, November 2, 2022 in [Today in BC podcast](#)


92 This argument assumes that transmission is so common that reducing risks of exposure no longer  
93 matters, as another exposure will occur soon thereafter. This is a strong claim, with major implications  
94 for both individual and public health decisions. It is essentially a claim that endemic levels of a disease  
95 such as COVID-19 are not under our control.

96 Mathematical models can help evaluate such claims and determine whether and to what extent our  
97 actions affect the endemic load of disease and mortality. Models can also predict how this load would  
98 change in the face of new variants and how this depends on the properties of those variants. Here, we  
99 tailor standard epidemiological models to the current phase of COVID-19 to better understand the risks  
100 posed by new variants and our ability to control endemic diseases.

101

## 102 **Model background**

103 We use a classic compartment model,  $SIR_n$ , as illustrated in Figure 2, measuring the fraction of the  
104 population that is in the susceptible class ( $S$ ), the infectious class ( $I$ ), or in one of several recovered  
105 classes ( $R_j$ ). These sequential recovered classes allow for different stages of waning immunity ( $i$ ,  
106 ranging from 1 to  $n$ ) and capture the dynamics of neutralizing antibodies that help protect against  
107 infection (Andrews et al. 2022; Khoury et al. 2021). When measured on a log scale, neutralizing  
108 antibodies rise to a high level soon after infection or vaccination and then decline linearly over time  
109 since vaccination and/or infection (e.g., (E. H. Lau et al. 2021; Evans et al. 2022; C. S. Lau et al. 2022;  
110 Jacobsen et al. 2023)). We thus consider the  $R_j$  classes to fall along different stages of this linear decline  
111 ( $R_1$  being highest and  $R_n$  lowest), with antibody levels falling over time (modeled as movement of  
112 individuals from  $R_j$  to  $R_{j+1}$ ) until levels are so low that infection is no longer prevented ( $R_n$  waning to  $S$ ).



113

114 **FIGURE 2: Epidemiological model used to predict impact of changing variants, behaviour,**  
 115 **and policy on endemic levels of disease.** We consider populations that have a high level of  
 116 immunity due to prior infection and/or vaccination and that consist of  $S$ : a susceptible fraction,  $I$ :  
 117 an infected fraction, and  $R_j$ : a recovered fraction with immunity at different stages of waning.  
 118 Parameters are  $\beta$ : transmission rate,  $\kappa$ : recovery rate,  $\delta_j$ : per-class waning rate per day, and  $v$ :  
 119 vaccination rate at the population level, all measured in the present-day population with prior  
 120 exposure. Movement between adjacent recovered classes is set equal to  $\delta_j = n\delta$ , so that the  
 121 expected time between first recovering and returning to the susceptible state is  $1/\delta$  days.

122 As we are modelling the long-term epidemiological dynamics in a population previously exposed to the  
 123 virus via vaccinations and/or infections, we emphasize that the susceptible class,  $S$ , consists of  
 124 individuals who have had previous exposure but are currently susceptible due to waning immunity.  
 125 Throughout this paper, we are thus describing the epidemiological dynamics in a previously challenged  
 126 population.

127 When we model vaccination, vaccines move individuals from the susceptible ( $S$ ) to the first recovered  
 128 class ( $R_1$ ) at rate  $v$  per population (Figure 2). We consider  $v$  to be the total fraction of the population  
 129 moved (rather than the rate per susceptible individual) to align with data on observed or target  
 130 vaccination rates within a country. Vaccination is therefore protective against infection in this model  
 131 until vaccine-induced immunity wanes, which occurs at the same rate that infection-induced immunity  
 132 wanes (although we do extend the model to consider the possibility that vaccination does not elicit an  
 133 immune reaction in some individuals). We do not separately model disease or severity, or vaccine's  
 134 effectiveness against these as distinct from protection against infection.

135 Before considering variants or NPI measures, the dynamics describing changes in the number of  
 136 individuals in each compartment within the  $SIR_n$  model are:

137 
$$\frac{dS}{dt} = \delta_n R_n - \beta SI - v$$

138 
$$\frac{dI}{dt} = \beta SI - \kappa I \tag{1}$$

139 
$$\frac{dR_1}{dt} = \kappa I + v - \delta_1 R_1$$

140 
$$\frac{dR_j}{dt} = \delta_{j-1} R_{j-1} - \delta_j R_j \quad \text{for } 2 \leq j \leq n.$$

141 We can find the equilibria of this system of equations by setting the derivatives to zero and solving,  
142 yielding two equilibria for the fraction of individuals in each class. One equilibrium corresponds to the  
143 disease being absent ( $\hat{S} = 1$ ), and the other to the disease being endemic:

144 
$$\hat{S} = \frac{\kappa}{\beta}$$

145 
$$\hat{I} = \left(1 - \frac{\kappa}{\beta}\right) \frac{\delta}{\delta + \kappa} - \frac{v}{\delta + \kappa} \quad (2)$$

146 
$$\hat{R}_j = \frac{1}{n} \left( \left(1 - \frac{\kappa}{\beta}\right) \frac{\kappa}{\delta + \kappa} + \frac{v}{\delta + \kappa} \right) \quad \text{for } 1 \leq j \leq n.$$

147 Importantly, because we are explicitly modelling endemic COVID-19 most individuals have previously  
148 been exposed to SARS-CoV-2, susceptibility and infectiousness may be lower in the current population  
149 than when the virus first appeared in humans because of cellular immunity, any residual humoral  
150 immunity among susceptible individuals (Tan et al. 2023), and/or due to any behavioural changes  
151 (including better ventilation, testing and self-isolation practices). For example, the rapid induction of  
152 cellular immunity reduces the viral load of typical breakthrough infections (Puhach et al. 2022),  
153 lowering transmission ( $\beta$ ) compared to a fully naïve population. The epidemiological dynamics in this  
154 endemic model thus depend on an "endemic basic reproductive number",  $\tilde{R}_0 \equiv \beta/\kappa$ , which is the basic  
155 reproductive number in a population consisting entirely of currently susceptible, but previously  
156 vaccinated or infected, individuals whose immunity has waned. In contrast to the initial  $R_0$  for COVID-  
157 19 at the time of its emergence, the parameters of the endemic model and in  $\tilde{R}_0$  (transmission,  $\beta$ , and  
158 recovery,  $\kappa$ ) refer to rates in this previously challenged population. Our estimates of  $\tilde{R}_0$  range from 1 to  
159 6 (Appendix 1), depending on estimates used for recovery rates, waning, and the endemic level of  
160 infections within a population, with a value of  $\tilde{R}_0 \approx 2$  for the parameters considered typical (Table S1).

161 If this previously challenged population were fully susceptible ( $\hat{S}$  near one), the disease would spread  
162 when rare as long as transmission rates were higher than recovery rates,  $\tilde{R}_0 = \frac{\beta}{\kappa} > 1$ , which we assume  
163 to hold. In this case, the endemic equilibrium (2) exists and is stable for all examples considered here.  
164 The endemic equilibrium may, however, be unstable (Hethcote, Stech, and Van Den Driessche 1981),  
165 leading to sustained cyclic dynamics, outside of the parameters used here (e.g., for  $n$  large enough).

166 The equilibrium can also be written in terms of  $\tilde{R}_0$  as:

167 
$$\hat{S} = \frac{1}{\tilde{R}_0}$$

168 
$$\hat{I} = \left(1 - \frac{1}{\tilde{R}_0}\right) \frac{\delta}{\delta + \kappa} - \frac{v}{\delta + \kappa} \quad (3)$$

$$169 \quad \hat{R}_j = \frac{1}{n} \left( \left( 1 - \frac{1}{\hat{R}_0} \right) \frac{\kappa}{\delta + \kappa} + \frac{v}{\delta + \kappa} \right) \quad \text{for } 1 \leq j \leq n.$$

170 Also of relevance is the number of bouts of disease that an individual expects per year, which is  
171  $365 \beta \hat{S} \hat{I} = 365 \kappa \hat{I}$ , assuming average behaviour (see Table S1).

172 Given that recovery rates are higher than waning rates ( $\delta \ll \kappa$ ), equation (3) shows that the number of  
173 infectious individuals at the endemic equilibrium is reduced by the number of vaccinations within a  
174 typical recovery period ( $v/\kappa$ ). If more vaccinations were to be given in a typical recovery period than  
175 the fraction of individuals expected to be infectious in the absence of vaccination, the disease could be  
176 driven extinct locally (though we note that in this model vaccination has a very high, if temporary,  
177 efficacy against infection, and that reintroductions are expected from importations, animal reservoirs,  
178 and chronic infections). Uptake of additional vaccine doses during 2023 has, however, been so low in  
179 many countries as to make little difference to the incidence and dynamics of SARS-CoV-2 (e.g., daily  
180 [annual] rates of 0.012% [4.7%] in France and 0.023% [8.8%] in the United States from 1 January – 30  
181 April, 2023; (Our World in Data 2023)). To simplify the discussion, we ignore ongoing vaccination for  
182 now, returning later to a discussion of the impact that vaccination uptake can have on individual risks of  
183 infection and on the overall incidence of disease.

#### 184 **Spread of variants during the endemic phase**

185 A new variant may spread within the population if it is more transmissible (e.g., better binding to ACE2  
186 receptors on host cells), more immune evasive, or both (see (Cao et al. 2023) for empirical measures for  
187 SARS-CoV-2). We can calculate the rate of spread of a variant using the  $SIR_n$  model by allowing  
188 different transmission rates for the resident variant ( $\beta$ ) and the new variant ( $\beta^* = \beta + \Delta\beta$ ) and by  
189 allowing immune evasive variants to infect earlier than the resident strain, while antibody levels are at  
190 intermediate levels. Specifically, we assume that an immune evasive variant can infect the last  $m$   
191 recovered classes (each of which is at frequency  $\hat{R}_j$  at the endemic equilibrium given by (3)), as well as  
192 susceptible individuals.

193 As described in Appendix 1, a new variant introduced into a population at the endemic equilibrium has a  
194 selective advantage of:

$$195 \quad s = \underbrace{\frac{\Delta\beta}{\beta} \kappa}_{\text{Transmission advantage}} + \underbrace{m \hat{R}_n \beta^*}_{\text{Evasion advantage}} \quad (4)$$

196 The selection coefficient,  $s$ , describes the rate at which the new variant spreads relative to the resident  
197 variant. Selection coefficients describing evolutionary changes in SARS-CoV-2 have been estimated in  
198 many jurisdictions using sequence information and are often relatively stable over time and space when  
199 measured consistently against the same reference strain (van Dorp et al. 2021; Otto et al. 2021).

200 What are the consequences of spreading variants for the incidence of disease? The incidence is initially  
201 expected to rise exponentially at rate proportional to selection (specifically,  $s \hat{I}$ ), but this is only transient  
202 as the new variant spreads through the susceptible population available to it. Over the long term, we  
203 show that the impact on the endemic level of disease depends strongly on whether the variant increases  
204 transmission rates and/or increases immune evasiveness, as well as the persistence of immune evasion  
205 during subsequent infections, even for variants with the same selective advantage.

206 In particular, when the population is comprised entirely of the new variant, the endemic level of disease  
207 changes to:

$$208 \quad \hat{I}^* = \left(1 - \frac{\kappa}{\beta + \Delta\beta}\right) \frac{\delta + \Delta\delta}{\delta + \Delta\delta + \kappa} \quad (5)$$


209 (found by solving equation (A1) for the endemic equilibrium when only the variant is present). The term  
210  $\Delta\delta$  refers to how the variant changes the rate of complete waning, from first entering the recovered class  
211 to returning to the susceptible state (i.e.,  $1/(\delta + \Delta\delta)$  is the mean number of days to return to  
212 susceptibility). [As short-hand, we refer to a variant's impact on immune evasion as a change in the  
213 waning rate  $\Delta\delta$ , but the model actually assumes log-antibody levels wane at a constant rate but the  
214 variants can just infect earlier, becoming susceptible sooner.]

215 Equation (5) allows us to evaluate the long-term impact of different types of variants. For immune  
216 evasive variants, the results are strongly dependent on the variant-specific immunity that develops after  
217 infection, even if the lineages have the same selective advantage and rate of spread ( $s$ , equation (4)).  
218 Consider two extreme possibilities:

- 219 • **Transient immune evasiveness:** If the variant better evades the initial suite of antibodies but  
220 causes infections that generate variant-specific immunity, subsequent infections may no longer  
221 be immune evasive. In this case, subsequent infections would require the full waning period  
222 (returning to the  $S$  compartment and not the  $R_i$  compartments), as for the resident strain. With  
223 only transient evasiveness, the long-term level of COVID-19 is *unaffected* ( $\Delta\delta = 0$ ).
- 224 • **Persistent immune evasiveness:** If the variant allows infections to occur earlier, both in the first  
225 and in subsequent infections, then the rate of return to susceptibility is consistently higher ( $\Delta\delta =$   
226  $\frac{m}{n-m}\delta$ ). With waning slow relative to recovery ( $\delta + \Delta\delta \ll \kappa$ ), persistently immune evasive  
227 variants cause the incidence of disease to *rise in proportion* to the increased rate of waning,  $\hat{I}^* \approx$   
228  $\hat{I} (1 + \Delta\delta/\delta)$ .

229 In either case, immune-evasive variants spread in the short-term because of the selective advantage,  $s$ ,  
230 gained by infecting susceptible individuals earlier, but the subsequent dynamics and long-term impact  
231 differ greatly, depending on whether variant-specific immunity builds (Figure 3). The extent to which  
232 exposure to a variant elicits variant-specific humoral or cellular immunity almost certainly falls between  
233 these two extremes. Metanalyses suggest, for example, that infections with Omicron are less protective  
234 against reinfection with Omicron, compared to the protective effects of pre-Omicron variants,  
235 suggesting some persistence in its immune-evasive properties (Arabi et al. 2023).





236 **FIGURE 3: Impact of the spread of immune evasive variants depends on whether a variant-**  
 237 **specific immune response is elicited.** Plots illustrate the dynamics over time of a more immune  
 238 evasive variant, which is able to infect earlier in the waning period (by  $m = 2$  out of  $n = 5$   
 239 recovered classes), giving the variant an  $s = 8.3\%$  selective advantage per day, which lies in the  
 240 range of the faster spreading variants observed in the past year (CoVaRR-Net’s CAMEO 2023).  
 241 While the short-term spread of the variant (dark shading taking over from light shading) and rise in  
 242 cases are nearly identical (given  $s$  is the same), the long-term consequences differ substantially  
 243 depending on whether the variant’s evasive properties are (panel A) transient or (panel B)  
 244 persistent. The endemic equilibrium rises only if evasiveness persists in subsequent infections  
 245 (panel B). We illustrate the dynamics in younger (under 70) and older (70+) individuals, who are  
 246 more prone to severe cases. Parameters:  $\kappa = 0.2$ ,  $\delta = 0.008$ ,  $\hat{I} = 2\%$ ,  $\beta = 0.42$ , the nominal  
 247 parameter estimates given in Appendix 1 for all age classes.

248 By contrast, more transmissible variants change the endemic equilibrium to:


$$249 \quad \hat{I}^* = \hat{I} \left( 1 + \frac{1}{\tilde{R}_0 - 1} \frac{\Delta\beta}{\beta + \Delta\beta} \right). \quad (6)$$

250 As a consequence:

- 251 • **More transmissible variants:** If the variant increases transmission rate, spread in the short term  
 252 depends directly on the change in transmission ( $s = (\Delta\beta/\beta) \kappa$ ; equation (4)), while the long-  
 253 term impact on the incidence of disease exhibits diminishing returns ( $\hat{I}^*/\hat{I}$  depends on  
 254  $\Delta\beta/(\beta + \Delta\beta)$ ). Thus, more transmissible variants have **a less than proportionate influence** on  
 255 the number of cases in the long term, unless the susceptible pool is large and  $\tilde{R}_0$  small ( $\hat{S} =$   
 256  $1/\tilde{R}_0 > 1/2$ ).

257 While more immune evasive variants increase the pool of susceptible individuals available to them (in  
 258 our model, by adding the last  $m$  recovered classes to the susceptible class), more transmissible variants  
 259 deplete the susceptible pool. This can be seen by the effect on the susceptible class at equilibrium, which  
 260 decreases from  $\hat{S} = \kappa/\beta$  for the resident virus to  $\hat{S}^* = \kappa/(\beta + \Delta\beta)$  for a more transmissible virus. For  
 261 this reason, more transmissible viruses are, to some extent, self-limiting and often have less of an effect  
 262 on the long-term number of cases than seen for a permanently immune evasive variant. Thus is  
 263 illustrated in Figure 4, which shows that the equilibrium rises less for a given % increase in

264 transmissibility (panel C) than for the same % increase in waning rate for a permanently immune  
265 evasive variant (panel B), unless  $\tilde{R}_0$  is so small that most individuals in the population are susceptible.  
266 Of course, variants may combine features affecting transmissibility and immune evasiveness (Cao et al.  
267 2023), as explored in Figure S1.




268 **FIGURE 4: Impact of the spread of a more transmissible variant.** Plot illustrates the dynamics  
269 over time of a more transmissible variant, which increases  $\beta$  (and hence  $\tilde{R}_0$ ) by 42%, chosen to  
270 give the variant the same selective advantage as in Figure 3 ( $s = 8.3\%$ ). While exhibiting a similar  
271 short-term rise in cases as in Figure 3, the long-term impact is intermediate. Parameters are  
272 identical to Figure 3, with  $\beta^* = 0.59$ .

273 This model predicts, as seen in the data over the past year (Figure 1), only modest rises and falls in case  
274 numbers, despite substantial evolutionary change in the frequency of different variants. This occurs  
275 because of the substantial population-level immunity that persists in the population at the endemic  
276 equilibrium. With a mixture of susceptible, infectious, and recovered individuals, the effective  
277 reproductive number at the endemic equilibrium must be one ( $R_{e,t} = 1$ ) for the resident and  $R_{e,t} = 1 +$   
278  $\Delta\beta/\beta$  for a more transmissible variant (e.g.,  $R_{e,t} = 1.42$  in Figure 4). Thus, only a modest drop in the  
279 susceptible population is needed ( $1/R_{e,t}$ ) before the infectious class peaks and falls again.

280 The robustness of these conclusions is explored in Appendix 2, considering different models of  
281 immunity (including leaky immunity) and the inclusion of features such as an exposed class and failure  
282 to seroconvert. The strength of selection (equation (4)) and the long-term impact on endemic levels of  
283 disease (equation (5)) are robustly observed. The speed at which the waves dissipate over time, however,  
284 is sensitive to model assumptions, stabilizing faster than observed above in many cases (Figure S2), so  
285 we caution that the nature of subsequent wavelets caused by the spread of a variant is hard to predict.

286 We conclude that variants may have dramatically different long-term impacts on the level of disease  
287 depending on the nature of the advantage (transiently or persistently immune evasive and/or more  
288 transmissible), despite exhibiting the same selective advantage and hence spreading at the same rate  
289 (e.g., with selection of  $s = 8.3\%$  per day in Figures 3 and 4). Indeed, a variant that is transiently immune  
290 evasive but less transmissible can spread and would be expected to reduce the equilibrium level of  
291 disease, except that once immunity to this variant has built, the previous resident reemerges because of  
292 its higher transmissibility (Figure S1B).

293 Figure 5 shows these long-term impacts on disease incidence at the endemic equilibrium across the  
 294 range of plausible parameters (Appendix 1). Transiently immune evasive variants have no long-term  
 295 impact (panel A), whereas the rise in cases is nearly proportional to the ability of a variant to evade  
 296 immunity, if that evasiveness is persistent, regardless of the exact parameter values (panel B). By  
 297 contrast, the long-term impact of a more transmissible variant depends strongly on the current  
 298 transmissibility, as measured by the endemic reproductive number. The larger  $\tilde{R}_0$  is, the smaller the  
 299 long-term impact of more transmissible variants is on disease levels (Figure 5C), essentially because the  
 300 pool of susceptible individuals is then smaller and rapidly depleted by more transmissible variants ( $\hat{S} =$   
 301  $1/\tilde{R}_0$ ). That said, for given waning ( $\delta$ ) and recovery ( $\kappa$ ) rates, the endemic level of disease is higher  
 302 when  $\tilde{R}_0$  is higher (equation (3)), so a small percentage increase in disease incidence can still have a  
 303 numerically important impact on the burden of disease.



304

305 **FIGURE 5: Long-term impact of a variant.** The percent change in the endemic equilibrium is  
 306 shown as a function of the percent by which the variant increases the rate at which recovered  
 307 individuals become susceptible again ( $\Delta\delta$ , panels A,B) or transmissibility ( $\Delta\beta$ , panel C).  
 308 Transiently immune evasive variants have no long-term impact, while persistently immune evasive  
 309 variants cause the endemic incidence of disease to rise nearly in proportion (dashed curve) across  
 310 all parameters considered plausible (purple shading, with the nominal parameter values illustrated  
 311 by a thick purple curve; see Appendix 1 and Table S1). By contrast, the impact of a more  
 312 transmissible variant that increases  $\beta$  depends strongly on  $\tilde{R}_0$  (but none of the other parameters),  
 313 leading to a less than proportional rise in cases whenever  $\tilde{R}_0 \geq 2$  (see equation (6)).

314 **Controlling an endemic disease** – In the face of variants that are increasingly transmissible and/or  
 315 persistently immune evasive, the endemic level of disease is expected to rise over time, but these  
 316 increases can be countered by protective measures at the individual and population level. Protective  
 317 measures range from vaccination to NPI measures, such as testing and self-isolation, avoiding crowded  
 318 indoor spaces, improving ventilation, and the wearing of well-fitting and high-quality masks (The Royal  
 319 Society 2023). Here we explore the impact of these protective measures at both the individual level,  
 320 modulating the frequency of infections, and the population level, modulating the endemic incidence of  
 321 disease.

322 **Vaccination** – Vaccination allows individuals to short-circuit the disease cycle by boosting antibody  
 323 levels and immunity by another dose rather than by infection. Globally, 65% of people have had the  
 324 primary series of COVID-19 vaccines but an average of only 0.35 booster doses have been distributed  
 325 per person ((Our World in Data 2023); accessed 22 August 2023). Jurisdictions vary widely in  
 326 recommended vaccine schedules and access to vaccines. For example, only individuals at higher risk of

327 serious illness are eligible for COVID-19 vaccinations in the United Kingdom (NHS 2023). In Canada,  
328 the National Advisory Committee on Immunization recommends that all adults be offered vaccines six  
329 months after the last dose or infection (NACI 2023). The Centre for Disease Control in the USA,  
330 however, recommends that individuals stay up to date with important vaccine updates (e.g., the updated  
331 mRNA vaccines providing protection against BA.4 and BA.5 in the fall of 2022 and against XBB in the  
332 fall of 2023 (CDC 2023)).

333 There is substantial uncertainty and confusion in both public and public health circles about the value of  
334 regular vaccinations against COVID-19 (Lin et al. 2023). Here, we explore one aspect: how much do  
335 regular vaccinations reduce the burden of disease expected at an endemic equilibrium?

336 We consider the impact of policies aimed at future vaccine uptake, encouraging vaccination of a portion  
337 of the population ( $v$ ) per day. Given that vaccines are recommended only after a substantial amount of time  
338 has passed since the previous dose or infection, these vaccinees are assumed to target individuals in the  
339 susceptible class, moving them into the first recovered class ( $S$  to  $R_1$ ; equation (1)). Unlike many  
340 previous epidemiological models (reviewed in (Scherer and McLean 2002)), we assume that the target  
341 vaccination rate is set by policy, adjusting public health campaigns, vaccine cost, and availability to  
342 meet these targets (i.e.,  $dS/dt$  in equation (1) declines by a fixed daily rate,  $v$ , rather than a per capita  
343 rate,  $vS$ ).

344 We consider vaccination rates in Canada as typical of what can be achieved when vaccines are available  
345 at regular intervals (every six months). From April-July 2023, vaccination rates in Canada have  
346 averaged only 0.012% of the population per day (annual rate of 4.5% (Health Infobase Canada 2023)).  
347 While these vaccinations help those individuals receiving a dose, this level has a negligible impact on  
348 the endemic level of cases (decreasing  $\hat{I}$  from 2% to 1.94% for the nominal parameter values). Many  
349 public health agencies have encouraged COVID-19 vaccine updates in the fall (Mahase 2023). For  
350 example, vaccination rates in Canada during September-December 2022 were 14 times higher (0.174%  
351 of the population per day, an annual rate of 63.5% (Health Infobase Canada 2023)), a rate that  
352 substantially lowers the endemic equilibrium level if maintained (from 2% to 1.16% for the nominal  
353 parameter values).


354 At an individual level, vaccination reduces the number of infections that one expects to have.  
355 Individuals on a regular six-month vaccination schedule are expected to be protected from neutralizing  
356 antibodies for  $1/\delta$  out of every 180 days. Calculating the probability of waning and infection before  
357 their next vaccine (equation (A2); Appendix 1), a regularly vaccinated individual expects to have about  
358 60% as many infections per year (0.88 vs 1.46) for the nominal parameter values (Appendix 1). Across  
359 the range of parameters considered plausible, vaccination every six months leads to only 40%-66% as  
360 many infections annually (supplementary *Mathematica* file).

361 At a population level, in our model, vaccination reduces the endemic level of infections to  $\hat{I}_v = \hat{I} - \frac{v}{\delta + \kappa}$   
362 (equation (2)). That is, the endemic level of infections is reduced by approximately the number of  
363 vaccinations conducted during the infectious period ( $v/\kappa$ , given that waning is considerably slower than  
364 recovery). Figure 6 illustrates the impact of increasing and maintaining the vaccination rate at the higher  
365 levels observed in Canada in the fall of 2022 ( $v = 0.174\%$ ). In this case, the long-term incidence of  
366 infection can be driven down by  $\sim 42\%$  (panel A). Across the range of parameters considered in  
367 Appendix 1, this population-level benefit ranging from a 12-100% decline in incidence of disease,  
368 falling at the lower end of the benefit when disease incidence is high without vaccination ( $\hat{I} = 4\%$ ) but

369 at the higher end and allowing complete eradication when disease incidence is low without vaccination  
370 ( $\hat{I} = 0.5\%$ ).

371 One policy option considered in many jurisdictions is to regularly vaccinate only the more vulnerable  
372 segment of the population. Figure 6B illustrates, however, that limiting vaccination to the more  
373 vulnerable population (shown here as vaccinating only those over 70 at a rate  $v = 0.174\%$ ) has less  
374 impact on the frequency of infections experienced by this vulnerable population (reduced by only 24%),  
375 because the incidence of COVID-19 remains high overall, increasing their risk of exposure.

376 That said, the additional protection provided by COVID-19 vaccines against severe disease, above and  
377 beyond the protection provided against infection, means that the risk of hospitalization and death can be  
378 lowered by vaccinating the vulnerable (Nyberg et al. 2022; Chemaitelly et al. 2022). Further reducing  
379 the risk of infection and severe disease, however, requires a broader vaccination campaign. Broad  
380 vaccination campaigns provide additional protection for the vulnerable, while also reducing the number  
381 of sick days, risks of long COVID, and severe disease among those not known to be vulnerable.



382  
383 **FIGURE 6: Impact of vaccination strategies.** Plots illustrate the dynamics over time when  
384 vaccination is increased to 0.174% of the population per day (annual rate of 63.5%), either (A)  
385 within the entire population or (B) limited to a more vulnerable population (illustrated as 70+ in  
386 age). Parameters are identical to Figure 3, with  $v = 0.00174$ .

387 As noted in Appendix 2, seroconversion rates upon vaccination are high (Wei et al. 2021), so we do not  
388 correct  $v$  for the small fraction of doses that fail to elicit an immune response. Not all individuals will,  
389 however, achieve high levels of immunity following vaccination and not all will be protected from  
390 infection. A mixture of induced immunity could be modelled by moving vaccinated individuals into a  
391 distribution of  $R_j$  classes. Additionally, some individuals being vaccinated may have been exposed in  
392 the recent past (i.e., coming from the infectious or recovered compartments, not solely from the  
393 susceptible classes). These possibilities are not explicitly modeled, although they would lower the  
394 protection offered by vaccination, akin to lowering  $v$ , and so require higher vaccination uptake to  
395 achieve the benefits described above.

396 *NPI measures* – A wide variety of non-pharmaceutical interventions have been deployed to counter the  
397 spread of SARS-CoV-2, including testing and self-isolation, enhancing ventilation and air filtration, and

398 wearing of high quality masks (see evaluation of evidence in the report (The Royal Society 2023)).  
399 Here, we consider the individual-level and population-level benefits of NPIs, as a function of their  
400 impact on preventing transmission of the virus, modelled by NPIs preventing a portion  $p$  of  
401 transmissions both from and to NPI users. Specifically, we assume that the NPI measures reduce  
402 transmission from  $\beta$  to  $(1 - p)\beta$  if one member in an interaction practices the measures and to  
403  $(1 - p)^2\beta$  if both do. The population is assumed to be heterogenous, as illustrated in Figure S4,  
404 consisting of a fraction  $f$  who regularly engage in NPI measures and are denoted by a  $\ddagger$  (compartments  
405  $S^\ddagger, I^\ddagger, R_j^\ddagger$  for  $j = 1$  to  $n$ , which sum to  $f$ ) and a fraction  $1 - f$  who do not (compartments  $S, I, R_j$ , which  
406 sum to  $1 - f$ ). See Appendix 3 for model details.

407 We first determine the benefit to an individual who adheres to NPI measures (e.g., masking). At the  
408 endemic equilibrium, an individual engaging in the NPI measure has a lower risk of being infected at  
409 any given point in time of:


410 Relative risk of infection: 
$$\frac{\hat{i}^\ddagger / f}{\hat{i} / (1-f)} = \frac{1}{1 + \hat{S} \frac{p}{(1-p)(1-f)}}, \quad (7)$$

411 where  $\hat{S}$  is the fraction of the population at the endemic equilibrium who are susceptible and do not  
412 engage in the NPI measure (given by (A11),  $\hat{S} \approx \kappa/\beta$  when  $f$  is small). This relative risk is  
413 mathematically equivalent to the relative rate at which individuals become infected for those who do  
414 versus do not engage in the NPI measure, as well as the relative number of infections expected per year.

415 Figure 7 illustrates the relative risk of infection (equation (7)). As expected, the more effective the NPI  
416 measure is (the higher  $p$ ) the lower the relative risk to individuals who engage in the NPIs (panel A).  
417 This individual-level benefit is only weakly dependent on the fraction of the population currently  
418 engaging in these measures ( $f = 10\%$ ,  $50\%$ , and  $90\%$  shown as solid, dashed, and dotted curves), with  
419 the relative risk rising slightly as  $f$  increases because non-practitioners gain a slight benefit from those  
420 who do practice the NPI measure.

421 The individual benefits depend strongly, however, on the endemic reproductive number of the disease  
422 ( $\tilde{R}_0$ ). At the nominal value of  $\tilde{R}_0 = 2$  and assuming low population-level uptake ( $f$  small), a person's  
423 relative risk of infection can be substantially reduced for NPIs that provide fairly modest protection (by  
424 14% and by 33% for  $p = 25\%$  and  $50\%$ , respectively). For  $\tilde{R}_0 = 6$  (on the high end of the range  
425 considered plausible; Appendix 1), however, these individual-level benefits diminish (to 5% and 14%  
426 for  $p = 25\%$  and  $50\%$ , respectively), because individuals are exposed so often that modestly protective  
427 NPIs only moderately delay infection.

428 Not only is a susceptible individual who regularly engages in NPI measures less likely to become  
429 infected when in contact with an infectious individual (by a factor  $1 - p$ ), but they are also less likely to  
430 pass the infection on to one of their contacts (by another factor  $1 - p$ ), compared to a non-practicing  
431 individual who is currently susceptible. Accounting for the proportion of time that practicing and non-  
432 practicing individuals are susceptible (as in equation (7)), the risk per unit time of being infectious and  
433 infecting a contact is substantially lowered for those engaging in NPI measures relative to those who do  
434 not (Figure 7B). This validates the approach used by many who adhere to NPI measures, such as  
435 masking, in order to protect vulnerable relatives and close contacts.



436

437

438

439

440

441

442

443

444

**FIGURE 7: Risk of infection for individuals regularly engaging in an NPI measure such as masking, relative to unmasked individuals.** Coloured lines illustrate different levels of protection,  $p$ , provided by the NPI measure, in a population where the fraction of individuals engaging in the NPI measure is  $f=10\%$  (solid),  $50\%$  (dashed), and  $90\%$  (dotted). Panel A shows the risk of infection and panel B the risk of becoming infected and infecting a contact for an individual engaging in NPI measures, relative to those who do not. The x-axis gives the endemic reproductive number in this heterogeneous population,  $\tilde{R}_0 = ((1-f) + f(1-p)^2) \beta / \kappa$ . Parameters: Relative risk depends on the parameters only through  $\tilde{R}_0$ ,  $f$ , and  $p$ .

445

446

447

The curvature of the relative risks in Figure 7 highlights the utility of multiple complementary interventions: other policies that reduce transmission (lowering  $\tilde{R}_0$ ) make masking more effective to individuals, because those individuals are less repeatedly exposed.

448

449

450

451

452

453

454

455

456

The individual-level benefits of NPI measures diminish with  $\tilde{R}_0$  (x-axis of Figure 7) because individuals practicing NPI measures are more likely than non-practitioners to have remained uninfected and so are more often susceptible at the time of exposure, which increases their relative risk of infection as  $\tilde{R}_0$  increases. Different results are obtained if individuals frequently switch their behaviour (e.g., masking some days and not others). Modifying the model as described by equation (A12), all individuals are then equally likely to be susceptible on any given day, and the NPI measure always reduces the risk of infection by a factor  $(1-p)$  for each practicing individual in an interaction. That is, the benefits remain at their maximal value of  $(1-p)$  in panel A and  $(1-p)^2$  in panel B, regardless of  $\tilde{R}_0$  and  $f$  (Appendix 3).

457

458

459

We next evaluate the population-level advantages of NPI measures by calculating the fraction of infected individuals expected at the endemic equilibrium ( $\hat{I} + \hat{I}^\ddagger$ ) when a fraction  $f$  of the population upholds these measures, relative to a population in which nobody does:

460

$$\text{Relative fraction of population infected: } \frac{\hat{I} + \hat{I}^\ddagger}{(\hat{I} + \hat{I}^\ddagger)_{f=0}} = (1 - \hat{S} - \hat{S}^\ddagger) \frac{\tilde{R}_0}{\tilde{R}_0 - 1}, \quad (8)$$

461


462

463

using the equilibrium values given by equation (A11). The right-hand side of equation (8) emphasizes that the population-wide benefits increase (fewer people will be infected) when there are more susceptible individuals available ( $\hat{S} + \hat{S}^\ddagger$  larger).

464 While the population-level impact is small when few individuals mask (left panel of Figure 8), there are  
465 substantial benefits to having moderate to high adherence to the NPI measures (central and right panel).  
466 These benefits are strongest when the endemic reproductive number is small, potentially moving the  
467 population away from the endemic case, where COVID-19 persists, to the disease-free equilibrium  
468 (when the curves cross the x-axis), again emphasizing the added benefits that come from combining  
469 interventions.

470 The reduction in cases caused by NPI measures is expected to result in a proportionate reduction in  
471 severe cases and deaths. Even a modest reduction (say 20%) can have non-linear benefits when  
472 hospitals are at capacity, improving care for all (Wichmann and Wichmann 2023). Achieving such  
473 benefits at a population level, however, requires that there be clear messaging and incentives to obtain  
474 the moderate to high levels of uptake required to impact population-wide infection rates.



475

476 **FIGURE 8: Reduction in cases at the endemic equilibrium when a fraction  $f$  of the**  
477 **population engages in an NPI measure, relative to when none do.** Coloured curves illustrate  
478 different levels of protection,  $p$ , provided by the NPI measure. Panels show the fraction of the  
479 population practicing the NPI measure: (A)  $f = 10\%$ , (B)  $50\%$ , and (C)  $90\%$ . The x-axis gives the  
480 endemic reproductive number in a population that is not engaging in the NPI measure, given by  
481  $\tilde{R}_0 = \beta/\kappa$ . Parameters: Reduction in cases depends on the parameters only through  $\tilde{R}_0$ ,  $f$ , and  $p$ .

## 482 Discussion –

483 This paper aims to expand our understanding of the impact of variants, as well as behavioural and public  
484 health measures, on endemic diseases like COVID-19. Widespread measures, both by individuals and  
485 public health agencies, repeatedly “flattened the curve” of COVID-19 during the first two years of the  
486 pandemic, reducing viral transmission to save lives and avoid collapse of health care systems (Ogden et  
487 al. 2022; Talic et al. 2021). Since mid-2022, however, COVID-19 has persisted at high levels throughout  
488 the world, becoming endemic with no sign of abating even during summer months. The mantra to  
489 “flatten the curve” is no longer relevant, as endemic levels are already fairly flat, and we lack a  
490 compelling guide to govern our collective behaviour in its place.

491 For COVID-19, endemic does not mean constant, with wavelets caused by variants, changing behaviour,  
492 and varying vaccination rates. Nor does endemic mean rare, as on-going high levels of COVID-19  
493 health impacts remain. Nor does endemic mean out of our control, as protective measures continue to  
494 have important benefits, boosting immunity through vaccination and reducing transmission through  
495 effective NPI measures. The goal of this paper is two-fold: to explore the impact of evolutionary



496 changes in the virus on disease incidence and to discuss how protective measures can counteract these  
497 rises, reducing disease risks.

498 Variants of endemic diseases that increase transmissibility and/or immune evasion are selectively  
499 favoured, with rises in frequency that can be measured empirically, yielding estimates of the strength of  
500 selection ( $s$ ). While the strength of selection accurately predicts the speed with which one variant  
501 replaces another, it does not predict the long-term impact on endemic levels of disease. For a given  
502 selection coefficient, we have shown that the long-term impact on disease is negligible for variants that  
503 are more immune evasive, but only transiently so, eliciting variant-specific antibodies that protect from  
504 reinfection (Figure 5A). By contrast, immune evasive variants that fail to elicit variant-specific  
505 antibodies have a persistent advantage, leading to a nearly proportional increase in cases in the long term  
506 (Figure 5B). In Appendix 2, we also consider variants that cause immunity to become leakier, increasing  
507 the risk of infection for all recovered classes, which are particularly problematic (Figure S3), causing a  
508 high long-term rise in cases because all individuals remain prone to infection if leakiness is persistent.  
509 Variants that are more transmissible generally have an intermediate impact on disease incidence (Figure  
510 5C). Thus, depending on the exact properties of new variants, we may see smaller or larger rises in cases  
511 over the long term, even for variants initially spreading at the same rate.

512 Lab assays of SARS-CoV-2 have dramatically sped up phenotypic assessment of new variants (Cao et  
513 al. 2023). Within days of new variants emerging, information has been shared by groups around the  
514 world, evaluating immune evasiveness (e.g., the titer of neutralizing antibodies in convalescent plasma  
515 required to prevent infection of cell lines) and efficiency of binding to ACE-2 receptors (e.g., via twitter,  
516 @yunlong\_cao). These assays often find that infection with one variant (e.g., BA.1) builds higher  
517 neutralizing capacity against that variant than other variants (e.g., BA.2), indicating some loss of  
518 immune evasiveness following infection with a variant (Cao et al. 2023). The impact on long-term  
519 immune evasion and reinfection rates for different variants remains an open question, and one whose  
520 answer determines the impact on endemic incidence of disease (Figure 5A,B).

521 We can counter variant-induced rises in cases, however, by encouraging higher uptake rates of vaccines  
522 and other non-pharmaceutical interventions. These measures always help individuals reduce their own  
523 risk of infection and the risk of infecting those around them (Figure 7). Widespread, but not universal,  
524 uptake is needed to substantially reduce levels of disease (Figure 8), except if the disease is near  
525 eradication ( $\tilde{R}_0$  near 1). The benefits could be enhanced by encouraging NPI measures around those who  
526 are most at risk of adverse outcomes and in places and times where risks of infection and/or the health  
527 care burden are high. Particularly valuable are investments in measures that protect all, regardless of  
528 uptake (such as improved air filtration and ventilation, adequate testing and job security to stay home  
529 when sick).

530 The models explored herein lack many important epidemiological details, including spatial and age  
531 structure in contact rates and seasonal variation in transmission risk. As such, the results are meant to  
532 guide expectations rather than provide precise predictions. Details were sacrificed in an effort to help us  
533 better understand how the endemic level of disease is likely to change in the future, in response to our  
534 efforts as well as further evolution of the virus.

### 535 **Supplementary Materials (FOR REVIEW)**

536 All proofs and code needed to generate the figures are available in *Mathematica* and PDF versions at  
537 <https://www.zoology.ubc.ca/~otto/Research/Endemic> (to be deposited in Dryad).

538 **Acknowledgements**

539 We thank all the authors, developers, and contributors to the VirusSeq database for making their  
540 SARS-CoV-2 sequences publicly available. We thank especially the Canadian Public Health Laboratory  
541 Network, academic sequencing partners, diagnostic hospital labs, and other sequencing partners for the  
542 provision of the Canadian sequence data used in Figure 1. The authors would like to thank the scientific  
543 community of the Coronavirus Variants Rapid Response Network (CoVaRR-Net), particularly Fiona  
544 Brinkman, Carmen Lia Murall, Jesse Shapiro, and Justin Yue for helpful discussions about variants.  
545 Funding was provided by the Natural Sciences and Engineering Research Council of Canada to SPO  
546 (RGPIN- 2022-03726), to AM (RGPIN-2022-03113), and to CC (CANMOD; RGPIN-2019-06624), by  
547 the Canada Research Chairs Program (SPO and AM) and the Canada 150 Research Chair Program (CC),  
548 and by the Canadian Institutes for Health Research (CIHR) operating grant to CoVaRR-Net.

549

550 **Declaration of Interests**

551 The authors declare no competing interests.

## 552 Appendix 1: Modelling the spread of variants

553 *Dynamics* – We include infections by a resident variant ( $I$ ) and a new variant ( $I^*$ ) in the SIR<sub>n</sub>  
554 epidemiological model illustrated in Figure 1. By allowing for multiple recovered classes, we can model  
555 new variants that are more immune evasive by allowing them to infect earlier in the waning period  
556 (infecting individuals in the last  $m$  recovered compartments  $R_j$ ), when antibody levels are high enough  
557 to prevent infection by the resident virus but not the new variant. The dynamics are then described by  
558 the following set of differential equations:

$$559 \quad \frac{dS}{dt} = \delta_n R_n - \beta SI - \beta^* SI^*$$

$$560 \quad \frac{dI}{dt} = \beta SI - \kappa I \qquad \frac{dI^*}{dt} = \beta^* (S + \sum_{j=1+n-m}^n R_j) I^* - \kappa I^* \qquad (A1)$$

$$561 \quad \frac{dR_1}{dt} = \kappa I + \kappa I^* - \delta_1 R_1$$

$$562 \quad \frac{dR_j}{dt} = \delta_{j-1} R_{j-1} - \delta_j R_j \qquad \text{for } 2 \leq j \leq n - m$$

$$563 \quad \frac{dR_j}{dt} = \delta_{j-1} R_{j-1} - \delta_j R_j - \beta^* R_j I^* \qquad \text{for } n - m < j \leq n$$

564 Setting all waning rates between recovered classes equal to  $\delta_i = \delta/n$  ensures that the average time from  
565 first recovering to returning to the susceptible class has a mean of  $1/\delta$  days. The distribution of waning  
566 times is then given by a gamma distribution with a coefficient of variation (CV) of  $1/\sqrt{n}$ , becoming  
567 more bell shaped with higher  $n$  (Hethcote, Stech, and Van Den Driessche 1981).

568 *Spread of a new variant* – The spread of a new variant into a population at the stable endemic  
569 equilibrium (equation (2)) is given by the leading eigenvalue,  $\lambda_L$  of the external stability matrix  
570 describing the dynamics of the variant (see details in the Supplementary *Mathematica* package), which  
571 equals:

$$572 \quad \lambda_L = \hat{S}\beta^* + m\hat{R}_j\beta^* - \kappa \qquad (A2)$$

573 If the new variant did not change the transmission rate ( $\beta^* = \beta$ ) and was unable to infect any additional  
574 sector of the population ( $m = 0$ ), it would be neutral ( $\lambda_L = 0$ , plugging in (2)).

575 The selection coefficient favouring a new variant is defined by the rise in frequency of the new variant  
576 relative to the old variant ( $\frac{dx}{dt} \equiv s x$ , where  $x = \text{freq}(\text{new variant})/\text{freq}(\text{old variant})$ ), which predicts an  
577 exponential rise in the relative frequency of the new variant over time ( $x_t = e^{st} x_0$ ). The strength of  
578 selection can thus be estimated empirically by the slope on a logit plot (plotting log of  $x_t$  over time).  
579 Near the endemic equilibrium, it can be shown that selection, defined in this way, equals  $\lambda_L$  (see  
580 Supplementary *Mathematica* package). Plugging in equation (2) for  $\hat{S}$  into (A2) then gives the selection  
581 coefficient reported in equation (4).

582 *Parameter values* – We consider the following parameter values for the current endemic phase during  
583 which Omicron predominates, giving the nominal value considered typical and the plausible range in  
584 square brackets:

- 585 •  $\kappa$  of 0.2 (mean of 5 days) [range of 3-10 days]. Source: Estimates of the infectious period for  
586 Omicron vary depending on the study design, but several studies are consistent with  
587 infectiousness for a couple of days prior to symptom onset and five days thereafter (UKHSA  
588 2023). We take into account some self-isolation upon infection and use a five-day average  
589 infectious period as a default.
- 590 •  $\delta$  of 0.008 (mean of 125 days) [range of 100-180 days]. Source: Waning rate depends on the  
591 exact sequence of vaccinations and infections. The half-life of protection against symptomatic  
592 infection with Omicron among studies summarized by Menegale et al. (Menegale et al. 2023)  
593 was 87 days without a booster and 111 days with a booster, yielding  $\delta$  values ranging from  
594 0.0071 to 0.0094 per day. Waning rates were similar for older and younger individuals  
595 (Menegale et al.'s eFigure 14).
- 596 •  $\hat{I}$  of 2% [range of 0.5%-4%]. Sources: The last report of the Coronavirus (COVID-19) Infection  
597 Survey UK (Office for National Statistics 2023), which assayed nose and throat swabs from  
598 households, found 2.66% of England were infected (13 March 2023). In Canada, models suggest  
599 that 1 in 28 were infected the week of 16 April 2023, while 1 in 80 were infected the week of 9  
600 September 2023 (COVID-19 Resources Canada 2023).
- 601 • Age structure for Canada: 13% of the population is 70+ in age (Statistics Canada 2023).

602 Combining these estimates with equations (2) and (3) allows estimation of the transmission rate and  
603 reproductive number. The nominal parameters given above yield estimates of  $\beta = 0.42$  and  $\tilde{R}_0 = 2.1$ ,  
604 ranging from  $\beta = \{0.11-2.27\}$  and  $\tilde{R}_0 = \{1.1,6.8\}$  (Table S1), although some combinations are not  
605 possible (e.g., a mean waning time of 180 days is inconsistent with an incidence of  $\hat{I} = 4\%$  if mean  
606 clearance times are too short,  $\kappa > 0.13$ ), and the disease is then expected to decline.

607 The expected number of disease bouts per year is 1.46 for the nominal parameter values, ranging from 0  
608 (when the disease disappears) to 2.92 when incidence is high ( $\hat{I} = 4\%$ ), waning is fast ( $\delta = 1/100$ ), and  
609 recovery is fast but not so fast that the disease disappears ( $\kappa = 1/5$ ).

610 We can also calculate the expected number of infections per year for an individual who is vaccinated at  
611 regular intervals (every  $T$  days). For simplicity, we make the approximation that vaccinations are  
612 frequent enough and waning slow enough that we need only consider the chance of one infection  
613 between vaccinations. If waning times were exponentially distributed, then the probability of becoming  
614 infected in the period between vaccinations would be:

$$\begin{aligned} 615 \quad P &= \int_0^T \underbrace{\delta e^{-\delta t}}_{\text{Waning at time } t} * \underbrace{(1 - e^{-\beta \hat{I}(T-t)})}_{\text{Probability of infection after waning}} dt & (A3) \\ 616 \quad &= 1 - \frac{e^{-\delta T} \beta \hat{I} - e^{-\beta \hat{I} T} \delta}{\beta \hat{I} - \delta}. \end{aligned}$$

617 The approximate annual number of infections is then  $365 P/T$ , which is 0.88 for those on a six-month  
618 vaccination interval ( $T = 365/2$ ) and the nominal parameter values ( $\kappa = 0.2$ ,  $\delta = 0.008$ ,  $\hat{I} = 2\%$ ,  $\beta =$   
619 0.42).

620

## 621 **Appendix 2: Model sensitivity and oscillatory behaviour**

622 Different choices about the number of recovered classes, movement among them, and whether immunity  
623 is leaky, as well as the inclusion of a latent period and incomplete seroconversion, were explored to  
624 determine sensitivity of the results to model assumptions (Supplementary *Mathematica* file). To  
625 simplify the presentation, we focus on the case where daily vaccination rates are low and are ignored  
626 (except where noted).

627 *Alternate models of recovery* – In the main text, we used multiple recovered classes in the SIR<sub>n</sub> model to  
628 capture observed declines in neutralizing antibodies, measured on a log scale, over time since  
629 vaccination and/or infection. While this reflects the dynamics of neutralizing antibody levels, a side  
630 consequence is that the distribution for the total waning time becomes increasingly bell shaped as  $n$  rises  
631 (CV of  $1/\sqrt{n}$ ). This synchronizes the recovery of individuals infected at the same time. If  $n$  is large  
632 enough, this synchronisation can destabilize the endemic equilibrium, leading to persistent cycles  
633 (Hethcote, Stech, and Van Den Driessche 1981). While the rise in frequency of a variant, as described  
634 by its selective advantage (equation (4)) and the long-term impact of the variant on the endemic  
635 equilibrium (equation (5)) are insensitive to the number of recovered compartments ( $n$ ), the extent of  
636 oscillations following the initial spread of the variant are much stronger as  $n$  increases (Figure S2, panels  
637 A-C). Empirically, the distribution of waning times is close to exponential (CV = 1; (Menegale et al.  
638 2023)), suggesting that intrinsic oscillations are likely to be damped (like Figure S2A, where CV = 1).

639 Similar behaviour to Figure S2A is seen in a model with only two recovered classes ( $n = 2$ ),  
640 corresponding to high ( $R_1$ ) and low ( $R_2$ ) antibody levels, where an immune evasive variant (but not the  
641 resident virus) can infect the second class. By setting the waning rates to  $\delta_1 = \delta/x$  (from  $R_1$  to  $R_2$ ) and  
642  $\delta_2 = \delta/(1 - x)$  (from  $R_2$  to S), the equilibrium fraction of recovered individuals in the second class ( $x$ )  
643 can be adjusted to allow for more immune evasive variants, while keeping the average time from first  
644 recovering to susceptibility at  $1/\delta$  days for the resident virus. This model has a nearly exponential  
645 waning time, with rapidly dampening oscillations, for more transmissible variants (Figure S2D), more  
646 immune evasive variants (Figure S2E), or both (Figure S2F). The selection coefficient and equilibrium  
647 remain unchanged, all else being equal (given by equations (4) and (5), respectively).

648 *Leaky immunity* – In the main text, we considered immunity to be polarized: individuals are either  
649 susceptible to infection ( $S$  compartment) or not ( $R_j$  compartments, with  $j$  depending on the variant).  
650 There is evidence, however, that SARS-CoV-2 immunity is leaky, such that high viral exposure can lead  
651 to infection for those who would otherwise be immune (Lind et al. 2023). Furthermore, variants may  
652 differ in the extent of leaky immune (e.g., (Lind et al. 2023) found higher hazard ratios following close  
653 exposure for Delta than for Omicron).

654 We thus explored variants that increased leakiness of immunity,  $\xi$ , in the SIR ( $n = 1$ ) and SIR<sub>n</sub> ( $n = 5$ )  
655 models (exploring the latter numerically only in the Supplementary *Mathematica* file). Incorporating  
656 leaky immunity in the SIR model changes the dynamics to:

657 
$$\frac{dS}{dt} = \delta R - \beta SI - \beta^* SI^*$$

$$658 \quad \frac{dI}{dt} = \beta SI + \xi \beta RI - \kappa I \quad \frac{dI^*}{dt} = \beta^* S I^* + \xi^* \beta^* R I^* - \kappa I^* \quad (A4)$$

$$659 \quad \frac{dR}{dt} = \kappa I + \kappa I^* - \xi \beta RI - \xi^* \beta^* R I^* - \delta R$$

660 The equilibrium is then:

$$661 \quad \hat{S} = \frac{1}{2}(-b + \sqrt{b^2 - 4c})$$

$$662 \quad \hat{I} = \frac{\delta \left(\frac{\kappa}{\beta} - \hat{S}\right)}{\hat{S} \xi \beta} \quad (A5)$$

663 where  $b = -\frac{\kappa - \delta - \xi \beta}{(1 - \xi)\beta}$  and  $c = -\frac{\kappa}{\beta} \frac{\delta}{(1 - \xi)\beta}$ . Selection on a variant then becomes:

$$664 \quad s = \underbrace{\frac{\Delta \beta}{\beta} \kappa}_{\text{Transmission advantage}} + \underbrace{\Delta \xi \hat{R} \beta^*}_{\text{Evasion advantage}} \quad (A6)$$

665 Figure S3 illustrates cases where immunity was robust against the resident virus ( $\xi = 0$ ) but leaky for  
 666 the variant ( $\xi^* > 0$ ), combined with some to no transmission advantage (panels A to C). Again we see  
 667 that the same selective advantage ( $s$ ) is consistent with substantially different long-term consequences  
 668 for endemic disease levels. Variants that exhibit leakier immunity greatly increase the endemic  
 669 equilibrium, more than seen in Figures 3 and 4 for a given selection coefficient, because all individuals  
 670 are more prone to infection in the long term, not just those with low antibody levels.

671 *Latent period* – Viral infections are characterized by a latent period between infection and detectable  
 672 viral load, which is thought to indicate the onset of the infectious period (UKHSA 2023). We can  
 673 include this period by adding to the SIR<sub>n</sub> model a latent class ( $E$ ), into which all new infections enter and  
 674 then exit at rate  $\epsilon$ . Including this period, the equilibrium fraction of infected individuals changes to:

$$675 \quad \hat{I} = \left(1 - \frac{\kappa}{\beta}\right) \frac{\delta \epsilon}{\epsilon \delta + \epsilon \kappa + \delta \kappa} \quad (A7)$$

676 Given that the rate of leaving the latent class is much faster than waning ( $\epsilon \gg \delta$ ), the last  $\delta \kappa$  term in the  
 677 denominator is negligible, and  $\epsilon$  cancels out of (A7). Thus, the equilibrium number of infections ( $\hat{I}$ ) is  
 678 nearly unaffected by including a latent class.

679 Recalculating the leading eigenvalue at this endemic equilibrium, the selection coefficient favoring the  
 680 new variant ( $s = \lambda_L$ ) changes slightly when a latent period is added, from  $s$  given by equation (4) to:

$$681 \quad s = -\frac{\epsilon + \kappa}{2} + \sqrt{\left(\frac{\epsilon + \kappa}{2}\right)^2 + s \epsilon} \quad (A8)$$

682 Assuming that the spread of the variant is slow relative to the latent and infectious periods ( $s \ll \epsilon, \kappa$ ),  
 683 adding a latent period causes selection to weaken slightly, with (A8) approaching  $s \frac{1}{1 + \kappa/\epsilon}$ . This occurs  
 684 because only during a fraction  $\frac{1/\kappa}{1/\epsilon + 1/\kappa} = \frac{1}{1 + \kappa/\epsilon}$  of the generation time of the virus is it infectious. Xin et  
 685 al. (Xin et al. 2023) estimate a mean latent period of 3.1 days for Omicron. For the parameters

686 considered typical of Omicron (Appendix 1), selection would be ~70% as strong with a latent period.  
687 We ignore this correction to simplify the model presentation.

688 *Seroconversion* – Another real-world complication is that not all individuals seroconvert following  
689 infection or vaccination (i.e., not all infections elicit a robust immune response). If a fraction  $q$  of  
690 infections boost immunity (meaning here that they recover to the  $R_1$  compartment in the  $SIR_n$  model),  
691 while  $1-q$  return become susceptible again (returning to the  $S$  compartment), the equilibrium fraction of  
692 infected individuals changes to:

$$693 \quad \hat{I} = \left(1 - \frac{\kappa}{\beta}\right) \frac{\delta/q}{\delta/q + \kappa}. \quad (A9)$$

694 Thus, decreasing the seroconversion rate by a factor  $q$  has the same effect on the endemic equilibrium as  
695 increasing the waning rate by a factor  $1/q$  (equation (5)), and the same holds for the selection coefficient  
696 of a variant,  $s$  (equation (4), supplementary *Mathematica* file). The temporal dynamics of the wavelets  
697 are slightly different, with immediate waning for those who do not seroconvert and slower waning for  
698 those who do (supplementary *Mathematica* file).

699 Seroconversion rates for vaccines can also be included, changing the equilibrium to:

$$700 \quad \hat{I} = \left(1 - \frac{\kappa}{\beta}\right) \frac{\delta/q}{\delta/q + \kappa} - \frac{v q_v/q}{\delta/q + \kappa}. \quad (A9)$$

701 where  $q_v$  is the seroconversion rate for vaccination (here meaning the probability that a vaccine dose  
702 boosts antibodies and provides protection from infection). If seroconversion rates are similar following  
703 infection and vaccination ( $q_v = q$ ), then the results for selection (equation (3)) and endemic incidence  
704 (equation (4)) are again the same if we replace  $\delta$  (ignoring seroconversion) with  $\delta/q$  (including it).

705 To simplify the presentation, we do not explicitly include seroconversion but consider a range of waning  
706 rates to cover both seroconversion and waning.

707 Empirically, high seroconversion rates have been reported following vaccination with a single dose of  
708 Pfizer's BNT162b2 ( $q = 99.5\%$ ) or AstraZeneca ChAdOx1 ( $q = 97.1\%$ ), leading to antibodies  
709 recognizing the spike protein (Wei et al. 2021). Slightly lower seroconversion ( $q = 93.5-95.3\%$ ) was  
710 observed following infection in early 2020 (Oved et al. 2020). An estimate following Omicron infection  
711 inferred even lower rates of seroconversion of  $q = 74-81\%$  (here examining antibodies to nucleocapsid,  
712 as anti-spike antibodies were nearly universal in the highly vaccinated population examined; (Erikstrup  
713 et al. 2022)).

### 714 **Appendix 3: Non-pharmaceutical interventions**

715 We consider an expansion of the  $SIR_n$  epidemiological model to allow heterogeneity in behaviour. As  
716 illustrated in Figure S4, we now allow two classes of individuals, those who regularly adhere to stronger  
717 NPI measures, such as masking (indicated by an ‡), and those who do not:

$$718 \quad \frac{dS}{dt} = \delta_n R_n - \beta SI - (1-p)\beta SI^\ddagger \quad \frac{dS^\ddagger}{dt} = \delta_n R_n^\ddagger - (1-p)\beta S^\ddagger I - (1-p)^2 \beta S^\ddagger I^\ddagger$$
$$719 \quad \frac{dI}{dt} = \beta SI + (1-p)\beta SI^\ddagger - \kappa I \quad \frac{dI^\ddagger}{dt} = (1-p)\beta S^\ddagger I + (1-p)^2 \beta S^\ddagger I^\ddagger - \kappa I^\ddagger \quad (A10)$$

$$\begin{aligned}
 720 \quad \frac{dR_1}{dt} &= \kappa I - \delta_1 R_1 & \frac{dR_1^\ddagger}{dt} &= \kappa I^\ddagger - \delta_1 R_1^\ddagger \\
 721 \quad \frac{dR_j}{dt} &= \delta_{j-1} R_{j-1} - \delta_j R_j & \frac{dR_j^\ddagger}{dt} &= \delta_{j-1} R_{j-1}^\ddagger - \delta_j R_j^\ddagger & \text{for } 2 \leq j \leq n
 \end{aligned}$$

722

723 where the last line of equations is repeated for the remaining waning classes ( $j$  from 2 to  $n$ ). We again  
 724 set all rates between waning classes to  $\delta_i = \delta/n$  (mean waning time of  $1/\delta$  days). The new parameter  $p$   
 725 measures the protection provided when one individual in an interaction engages in NPI measures  
 726 (reducing  $\beta$  by a factor  $1-p$ ). If both infected and susceptible individuals uphold these measures,  
 727 transmission is reduced by  $(1-p)^2$ . All variables are measured as proportions of the total population,  
 728 with  $f$  being the fraction of the population carrying out NPI measures, such as masking (the sum of the  $\ddagger$   
 729 variables).

730 There are two equilibria of this system (A10), one where the disease is absent and one where the disease  
 731 is endemic at:

$$\begin{aligned}
 732 \quad \hat{S} &= \frac{1}{2}(-B + \sqrt{B^2 - 4C}) & \hat{S}^\ddagger &= \frac{\kappa - \beta \hat{S}}{(1-p)^2 \beta} \\
 733 \quad \hat{I} &= (1 - f - \hat{S}) \frac{\delta}{\delta + \kappa} & \hat{I}^\ddagger &= (1 - f - \hat{S}) \frac{\delta}{\delta + \kappa} \frac{\kappa - \beta \hat{S}}{(1-p) \beta \hat{S}} & (A11) \\
 734 \quad \hat{R}_j &= \hat{R}_{j-1} = \frac{1 - f - \hat{S} - \hat{I}}{n} & \hat{R}_j^\ddagger &= \hat{R}_{j-1}^\ddagger = \frac{f - \hat{S} - \hat{I}}{n} & \text{for } 1 \leq j \leq n
 \end{aligned}$$

735

736 where  $B = \frac{(1-f)(1-p)\beta + f(1-p)^2\beta - \kappa p}{p\beta}$  and  $C = -\frac{(1-f)(1-p)\kappa}{p\beta}$ . The disease-absent equilibrium is locally  
 737 stable when transmission rates are low relative to clearance, such that the endemic reproductive number  
 738 if everyone were susceptible is less than one,  $\tilde{R}_0 = \frac{(1-f)\beta + f(1-p)^2\beta}{\kappa} < 1$ , in which case the endemic  
 739 equilibrium does not exist (i.e., not all variables are positive). Otherwise, when  $\tilde{R}_0 > 1$ , the endemic  
 740 equilibrium exists and is stable for the parameters considered, but it may become unstable for large  $n$   
 741 (Hethcote, Stech, and Van Den Driessche 1981).

742 At this equilibrium, the risk that an individual is in the infected class at any point in time is  $\hat{I}^\ddagger/f$  if they  
 743 regularly mask and  $\hat{I}/(1-f)$  if they do not, from which we calculate the relative risk in the main text.  
 744 The population-level impact of NPI measures, such as masking, is determined by analysing the fraction  
 745 of the population expected to be infected at any point in time,  $\hat{I} + \hat{I}^\ddagger$ .

746 The above assumes that an individual's choice about engaging in NPI measures remains constant over  
 747 time, but we also consider the opposite case (detailed in the Supplementary *Mathematica* file), where  
 748 individuals rapidly switch between engaging or not in NPI measures. Assuming that the behaviour  
 749 persists over the short time frame of an infection but that individuals switch often while in the longer  
 750 susceptible or recovered phases, we can simplify the model by monitoring only those engaging in NPI  
 751 measures at the time of exposure, with  $f$  then representing the probability that an individual engages in



752 the NPI measures at that time. We thus only sub-divide the infectious class into those who were or were  
753 not practicing the NPI measures at the time of infection ( $I^\ddagger$  or  $I$ , respectively). The dynamics are then:

$$754 \quad \frac{dS}{dt} = \delta_n R_n - (1-f)\beta SI - (1-p)f\beta SI - (1-p)(1-f)\beta SI^\ddagger - (1-p)^2 f\beta SI^\ddagger \quad (\text{A12})$$

$$755 \quad \frac{dI}{dt} = (1-f)\beta SI + (1-p)(1-f)\beta SI^\ddagger - \kappa I \quad \frac{dI^\ddagger}{dt} = (1-p)f\beta SI + (1-p)^2 f\beta SI^\ddagger - \kappa I^\ddagger$$

$$756 \quad \frac{dR_1}{dt} = \kappa I + \kappa I^\ddagger - \delta_1 R_1$$

$$757 \quad \frac{dR_j}{dt} = \delta_{j-1} R_{j-1} - \delta_j R_j \quad \text{for } 2 \leq j \leq n$$

758 Results using (A12) instead of (A10) are similar, except that practicing and non-practicing individuals  
759 are equally likely to be susceptible at the time of exposure, so that the individual-level protective effect  
760 of the NPI measure now depends only on  $p$  and not on  $\tilde{R}_0$ , as discussed in the text.

761 *Parameters:* The protection ( $p$ ) and uptake ( $f$ ) depend on the NPI measure considered (The Royal  
762 Society 2023). Here we briefly review data on masking as a protective measure. One metaanalysis of  
763 randomized control studies prior to the COVID-19 pandemic found protection provided by masks was  $p$   
764 = 16% for respiratory infections, rising to  $p = 24\%$  in studies longer than two weeks (Li et al. 2022).  
765 Importantly, many individual studies were underpowered but the results were consistent across studies  
766 (see Figure 2 in Li et al. 2022).

767 For COVID-19, a metaanalysis of the impact of mask mandates estimated a 25% reduction in  
768 transmission rates, comparing transmission levels predicted if everyone were in the class that self-report  
769 wearing masks “most of the time in some public places” to that if no one wore masks (Leech et al.  
770 2022). Importantly, the authors showed that the lifting or imposition of mandates rarely had dramatic  
771 immediate effects on mask wearing, emphasizing that mandates are a poor proxy for mask wearing.  
772 Their analysis thus benefited from a global analysis of trends in mask-wearing behavior around the time  
773 of mandates by incorporating data from a survey of masking behaviour among nearly 20 million  
774 individuals.


775 As argued by Leech et al. (2022), this effect size is likely to be underestimated for a number of reasons.  
776 First, the study period (1 May – 1 September 2020) occurred when cloth masks predominated, because  
777 high-quality masks were largely unavailable outside of health care settings. Second, the definition of  
778 mask use was broad and included individuals who only occasionally mask and do so in few public  
779 places. We thus consider that  $p = 0.25$  represents a lower bound on the protection provided by masking.

780 Higher values are plausible when using high-quality masks and doing so consistently in indoor public  
781 spaces. For example, masks provided a stronger benefit, reducing the odds ratio of infection by an  
782 average of 50% among the studies summarized within healthcare settings (The Royal Society 2023). We  
783 thus consider  $p = 0.5$  to represent a reasonable upper bound on the protection provided by masking  
784 attainable by consistent wearing of high-quality masks. Combinations of NPI measures, including  
785 improved ventilation, avoiding crowded indoor environments, testing and self-isolation, and masking  
786 may provide considerably stronger protection.


787 **Table S1: Parameter estimates and inferred rates.** The first three columns are estimated from the  
 788 literature (Appendix 1). Using equation (2), these parameters provide estimates for the transmission rate  
 789 ( $\beta$ ), the endemic reproductive number ( $\tilde{R}_0 = \beta/\kappa$ ), the fraction of susceptible individuals ( $\hat{S}$ ), and the  
 790 estimated annual number of infections at the endemic equilibrium (inferred values are in italics). The  
 791 first row gives the nominal parameter values used in the text. “NA” are parameter combinations that do  
 792 not sustain an endemic equilibrium of the disease. Estimates are given without ongoing vaccination ( $v =$   
 793  $0$ ) but are nearly identical with low rates, as in Canada during the summer of 2023 ( $v = 0.00012$ , all  
 794 differences  $<12\%$ ; see supplementary *Mathematica* file for estimates with higher rates of vaccination).

Incidence ( $\hat{I}$ )	Waning rate ( $\delta$ )	Recovery rate ( $\kappa$ )	Transmission rate ( $\beta$ )	Reproductive number ( $\tilde{R}_0$ )	Susceptible ( $\hat{S}$ )	Annual # of infections
<b>0.02</b>	<b>0.008</b>	<b>0.2</b>	<b><i>0.417</i></b>	<b><i>2.083</i></b>	<b><i>0.48</i></b>	<b><i>1.46</i></b>
0.02	0.008	0.333	<i>2.273</i>	<i>6.818</i>	<i>0.147</i>	<i>2.433</i>
0.02	0.008	0.1	<i>0.137</i>	<i>1.37</i>	<i>0.73</i>	<i>0.73</i>
0.02	0.01	0.2	<i>0.345</i>	<i>1.724</i>	<i>0.58</i>	<i>1.46</i>
0.02	0.01	0.333	<i>1.064</i>	<i>3.191</i>	<i>0.313</i>	<i>2.433</i>
0.02	0.01	0.1	<i>0.128</i>	<i>1.282</i>	<i>0.78</i>	<i>0.73</i>
0.02	0.006	0.2	<i>0.769</i>	<i>3.846</i>	<i>0.26</i>	<i>1.46</i>
0.02	0.006	0.333	NA	NA	NA	NA
0.02	0.006	0.1	<i>0.161</i>	<i>1.613</i>	<i>0.62</i>	<i>0.73</i>
0.005	0.008	0.2	<i>0.23</i>	<i>1.149</i>	<i>0.87</i>	<i>0.365</i>
0.005	0.008	0.333	<i>0.424</i>	<i>1.271</i>	<i>0.787</i>	<i>0.608</i>
0.005	0.008	0.1	<i>0.107</i>	<i>1.072</i>	<i>0.932</i>	<i>0.182</i>
0.005	0.01	0.2	<i>0.223</i>	<i>1.117</i>	<i>0.895</i>	<i>0.365</i>
0.005	0.01	0.333	<i>0.402</i>	<i>1.207</i>	<i>0.828</i>	<i>0.608</i>
0.005	0.01	0.1	<i>0.106</i>	<i>1.058</i>	<i>0.945</i>	<i>0.182</i>
0.005	0.006	0.2	<i>0.245</i>	<i>1.227</i>	<i>0.815</i>	<i>0.365</i>
0.005	0.006	0.333	<i>0.48</i>	<i>1.439</i>	<i>0.695</i>	<i>0.608</i>
0.005	0.006	0.1	<i>0.11</i>	<i>1.105</i>	<i>0.905</i>	<i>0.182</i>
0.04	0.008	0.2	NA	NA	NA	NA
0.04	0.008	0.333	NA	NA	NA	NA
0.04	0.008	0.1	<i>0.217</i>	<i>2.174</i>	<i>0.46</i>	<i>1.46</i>
0.04	0.01	0.2	<i>1.25</i>	<i>6.25</i>	<i>0.16</i>	<i>2.92</i>
0.04	0.01	0.333	NA	NA	NA	NA
0.04	0.01	0.1	<i>0.179</i>	<i>1.786</i>	<i>0.56</i>	<i>1.46</i>
0.04	0.006	0.2	NA	NA	NA	NA
0.04	0.006	0.333	NA	NA	NA	NA
0.04	0.006	0.1	<i>0.417</i>	<i>4.167</i>	<i>0.24</i>	<i>1.46</i>

795




796 **FIGURE S1: Variants combining immune evasiveness and changes in transmissibility.** Panel A:  
797 Variant is persistently immune evasive (by half the amount shown in Figure 3B, able to infect  $m = 1$  out  
798 of  $n = 5$  recovered classes) and more transmissible (increasing  $\beta$ , and hence  $\tilde{R}_0$ , by 17%). Panel B:  
799 Variant is even more immune evasive (50% more than in Figure 3B, able to infect  $m = 3$  out of  $n = 5$   
800 recovered classes) and less transmissible (decreasing  $\beta$ , and hence  $\tilde{R}_0$ , by 17%), with immune evasion  
801 being transient. In both cases,  $\beta^*$  was chosen to give the variant the same selective advantage as in  
802 Figure 3 ( $s = 8.3\%$ ), leading to the same initial rate of spread of the variant (dark shading) in a resident  
803 population of viruses (light shading). Because the variant is only transiently immune evasive in Panel B,  
804 the resident lineage, which is more transmissible, eventually takes over. Parameters:  $\kappa = 0.2$ ,  $\delta =$   
805  $0.008$ ,  $\hat{I} = 2\%$ ,  $\beta = 0.42$ . the nominal parameter estimates given in Appendix 1 for all age classes.



806


807 **FIGURE S2: Robustness to model structure.** Panels (A)-(C) illustrate the sensitivity of the dynamics  
808 to the number of recovery classes ( $n$ ) for a more transmissible variant that increases  $\beta$  by 42% (panel B  
809 is equivalent to Figure 3). Holding the expected waning period constant at  $1/\delta = 125$  days, increasing  
810 the number of compartments causes a more bell-shaped distribution of the waning period and increases  
811 oscillations following the spread of the variant (from panel A to C). Panels (D)-(F) consider two  
812 recovered compartments ( $n = 2$ ), corresponding to high and low neutralizing antibody levels. At the  
813 endemic equilibrium, either 40% ( $x = 0.4$ ; panels D, E) or 20% ( $x = 0.2$ , panel F) of recovered  
814 individuals are in the low-immunity compartment, which can be infected by a more immune evasive  
815 variant (panels E and F). The variant in panel (D) is only more transmissible. In each case, the  
816 transmissibility of the variant is adjusted to hold its selective advantage constant at ( $s = 8.3\%$ ),  
817 increasing  $\beta$  by (A)-(D) 42%, (E) 0%, and (F) 17%. Parameters:  $\kappa = 0.2$ ,  $\delta = 0.008$ ,  $\hat{I} = 2\%$ ,  $\beta =$   
818  $0.42$ , the nominal parameter estimates given in Appendix 1 for all age classes.

819



820

821 **FIGURE S3: Robustness to model structure: allowing leaky immunity.** Panels illustrate the standard  
822 SIR model ( $n = 1$ ) when variants increase leakiness of immunity. Individuals infectious with the variant  
823 can infect all recovered individuals with a transmission rate that is (A)  $\xi = 10\%$ , (B)  $20\%$ , and (C)  $40\%$   
824 times  $\beta$ , whereas individuals carrying the resident virus can only infect susceptible individuals ( $\xi = 0$ ).  
825 In each case, the transmissibility of the variant is adjusted to hold its selective advantage constant at  $s =$   
826  $8.3\%$ , which required increasing  $\beta$  by (A)  $28\%$ , (B)  $17\%$ , and (C)  $0\%$ . Note that the y-axis has been  
827 increased relative to previous figures due to the greater long-term impact of variants able to infect all  
828 recovered classes by increasing the leakiness of immunity. Parameters:  $\kappa = 0.2$ ,  $\delta = 0.008$ ,  $\hat{I} = 2\%$ ,  
829  $\beta = 0.42$ , the nominal parameter estimates given in Appendix 1 for all age classes.



830

831 **FIGURE S4: Epidemiological model used to explore the benefits of NPI measures, such as**  
 832 **masking.** We include behavioural heterogeneity in  $SIR_n$  model, where variables with a  $\ddagger$  denote  
 833 individuals engaging in the NPI measure(s). As before,  $S$  are susceptible individuals,  $I$  are infectious,  
 834 and  $R_n$  are recovered, with immunity at different stages of waning. The fraction of individuals engaging  
 835 in NPI measures is  $f = S^\ddagger + I^\ddagger + \sum_{i=1}^n R_i^\ddagger$ . See Supplementary *Mathematica* file for an alternative  
 836 model where individuals rapidly switch behaviours (switching between the upper and lower row of  
 837 circles). Parameters are  $\beta$ : transmission rate,  $p$ : protection provided by masking (modeled as a reduction  
 838 in transmission by a factor  $(1-p)$  for each person in an interaction wearing a mask),  $\kappa$ : recovery rate, and  
 839  $\delta_j$ : per-class waning rate.

840 **References [Format will be finalized following review]**

- 841 Andrews, Nick, Julia Stowe, Freja Kirsebom, Samuel Toffa, Tim Rickeard, Eileen Gallagher, Charlotte  
842 Gower, et al. 2022. “Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.”  
843 *The New England Journal of Medicine* 386 (16): 1532–46.
- 844 Arabi, Maryam, Yousef Al-Najjar, Omna Sharma, Ibtihal Kamal, Aimen Javed, Harsh S. Gohil, Pradipta  
845 Paul, Aljazi M. Al-Khalifa, Sa’ad Laws, and Dalia Zakaria. 2023. “Role of Previous Infection  
846 with SARS-CoV-2 in Protecting against Omicron Reinfections and Severe Complications of  
847 COVID-19 Compared to Pre-Omicron Variants: A Systematic Review.” *BMC Infectious  
848 Diseases* 23 (1): 432.
- 849 Canadian Blood Services. 2023. “COVID-19 Seroprevalence Report July 28, 2023.” 2023.  
850 [https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/08/covid-19-full-report-  
851 june-2023.pdf](https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/08/covid-19-full-report-june-2023.pdf).
- 852 Cao, Yunlong, Fanchong Jian, Jing Wang, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Jing Wang,  
853 et al. 2023. “Imprinted SARS-CoV-2 Humoral Immunity Induces Convergent Omicron RBD  
854 Evolution.” *Nature* 614 (7948): 521–29.
- 855 CDC. 2023. “Stay Up to Date with COVID-19 Vaccines.” Stay Up to Date with COVID-19 Vaccines.  
856 2023. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>.
- 857 Chemaitelly, Hiam, Houssein H. Ayoub, Sawsan AlMukdad, Peter Coyle, Patrick Tang, Hadi M.  
858 Yassine, Hebah A. Al-Khatib, et al. 2022. “Duration of mRNA Vaccine Protection against  
859 SARS-CoV-2 Omicron BA.1 and BA.2 Subvariants in Qatar.” *Nature Communications* 13 (1):  
860 3082.
- 861 CoVaRR-Net’s CAMEO. 2023. “Duotang, a Genomic Epidemiology Analyses and Mathematical  
862 Modelling Notebook.” Duotang. 2023. <https://covarr-net.github.io/duotang/duotang.html>.
- 863 COVID-19 Resources Canada. 2023. “Detailed Forecasts: CAN, Followed by Each Province on  
864 Subsequent Pages.” Detailed Forecasts: CAN, Followed by Each Province on Subsequent Pages.  
865 2023. <https://covid19resources.ca/covid-hazard-index/>.
- 866 Day, Troy, Sylvain Gandon, Sébastien Lion, and Sarah P. Otto. 2020. “On the Evolutionary  
867 Epidemiology of SARS-CoV-2.” *Current Biology: CB* 30 (15): R849–57.
- 868 Dorp, Christiaan H. van, Emma E. Goldberg, Nick Hengartner, Ruian Ke, and Ethan O. Romero-  
869 Severson. 2021. “Estimating the Strength of Selection for New SARS-CoV-2 Variants.” *Nature  
870 Communications* 12 (1): 7239.
- 871 Erikstrup, Christian, Anna Damkjær Laksafoss, Josephine Gladov, Kathrine Agergård Kaspersen, Susan  
872 Mikkelsen, Lotte Hindhede, Jens Kjærgaard Boldsen, et al. 2022. “Seroprevalence and Infection  
873 Fatality Rate of the SARS-CoV-2 Omicron Variant in Denmark: A Nationwide Serosurveillance  
874 Study.” *The Lancet Regional Health. Europe* 21 (October): 100479.
- 875 Evans, John P., Cong Zeng, Claire Carlin, Gerard Lozanski, Linda J. Saif, Eugene M. Oltz, Richard J.  
876 Gumina, and Shan-Lu Liu. 2022. “Neutralizing Antibody Responses Elicited by SARS-CoV-2  
877 mRNA Vaccination Wane over Time and Are Boosted by Breakthrough Infection.” *Science  
878 Translational Medicine* 14 (637): eabn8057.
- 879 Health Infobase Canada. 2023. “COVID-19 Vaccination: Doses Administered.” COVID-19  
880 Vaccination: Doses Administered. 2023. [https://health-infobase.canada.ca/covid-19/vaccine-  
881 administration/](https://health-infobase.canada.ca/covid-19/vaccine-administration/).
- 882 Hethcote, Herbert W., Harlan W. Stech, and P. Van Den Driessche. 1981. “Nonlinear Oscillations in  
883 Epidemic Models.” *SIAM Journal on Applied Mathematics* 40 (1): 1–9.
- 884 Jacobsen, Henning, Ioannis Sitaras, Maeva Katzmarzyk, Viviana Cobos Jimenez, Robert Naughton,  
885 Melissa M. Higdon, and Maria Deloria Knoll. 2023. “Waning of Post-Vaccination Neutralizing  
886 Antibody Responses against SARS-CoV-2, a Systematic Literature Review and Meta-Analysis.”  
887 *MedRxiv*. <https://doi.org/10.1101/2023.08.08.23293864>.

- 888 Keeling, Matt J., and Pejman Rohani. 2011. *Modeling Infectious Diseases in Humans and Animals*.  
889 Princeton University Press.
- 890 Khoury, David S., Deborah Cromer, Arnold Reynaldi, Timothy E. Schlub, Adam K. Wheatley, Jennifer  
891 A. Juno, Kanta Subbarao, Stephen J. Kent, James A. Triccas, and Miles P. Davenport. 2021.  
892 “Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic  
893 SARS-CoV-2 Infection.” *Nature Medicine* 27 (7): 1205–11.
- 894 Lau, Chin Shern, May Lin Helen Oh, Soon Kieng Phua, Ya-Li Liang, and Tar Choon Aw. 2022. “210-  
895 Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of  
896 BNT162b2 mRNA Vaccine.” *Vaccines* 10 (10). <https://doi.org/10.3390/vaccines10101703>.
- 897 Lau, Eric Hy, David Sc Hui, Owen Ty Tsang, Wai-Hung Chan, Mike Yw Kwan, Susan S. Chiu, Samuel  
898 Ms Cheng, et al. 2021. “Long-Term Persistence of SARS-CoV-2 Neutralizing Antibody  
899 Responses after Infection and Estimates of the Duration of Protection.” *EClinicalMedicine* 41  
900 (November): 101174.
- 901 Leech, Gavin, Charlie Rogers-Smith, Joshua Teperowski Monrad, Jonas B. Sandbrink, Benedict Snodin,  
902 Robert Zinkov, Benjamin Rader, et al. 2022. “Mask Wearing in Community Settings Reduces  
903 SARS-CoV-2 Transmission.” *Proceedings of the National Academy of Sciences of the United  
904 States of America* 119 (23): e2119266119.
- 905 Li, Hui, Kai Yuan, Yan-Kun Sun, Yong-Bo Zheng, Ying-Ying Xu, Si-Zhen Su, Yu-Xin Zhang, et al.  
906 2022. “Efficacy and Practice of Facemask Use in General Population: A Systematic Review and  
907 Meta-Analysis.” *Translational Psychiatry* 12 (1): 49.
- 908 Lin, Cheryl, Brooke Bier, Rungting Tu, John J. Paat, and Pikuei Tu. 2023. “Vaccinated Yet Booster-  
909 Hesitant: Perspectives from Boosted, Non-Boosted, and Unvaccinated Individuals.” *Vaccines* 11  
910 (3). <https://doi.org/10.3390/vaccines11030550>.
- 911 Lind, Margaret L., Murilo Dorion, Amy J. Houde, Mary Lansing, Sarah Lapidus, Russell Thomas, Inci  
912 Yildirim, et al. 2023. “Evidence of Leaky Protection Following COVID-19 Vaccination and  
913 SARS-CoV-2 Infection in an Incarcerated Population.” *Nature Communications* 14 (1): 5055.
- 914 Mahase, Elisabeth. 2023. “Covid-19: Annual Flu-like Booster Approach May Not Be Appropriate, Says  
915 Expert on Infectious Disease.” *BMJ* 380 (January): 196.
- 916 Menegale, Francesco, Mattia Manica, Agnese Zardini, Giorgio Guzzetta, Valentina Marziano, Valeria  
917 d’Andrea, Filippo Trentini, Marco Ajelli, Piero Poletti, and Stefano Merler. 2023. “Evaluation of  
918 Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-  
919 Analysis.” *JAMA Network Open* 6 (5): e2310650.
- 920 NACI. 2023. “Guidance on the Use of COVID-19 Vaccines in the Fall of 2023.” Public Health Agency  
921 of Canada. [https://www.canada.ca/content/dam/phac-  
922 aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-  
923 immunization-guidance-use-covid-19-vaccines-fall-2023/statement.pdf](https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-use-covid-19-vaccines-fall-2023/statement.pdf).
- 924 NHS. 2023. “About COVID-19 Vaccination.” About COVID-19 Vaccination. 2023.  
925 <https://www.nhs.uk/conditions/covid-19/covid-19-vaccination/about-covid-19-vaccination/>.
- 926 Nyberg, Tommy, Neil M. Ferguson, Sophie G. Nash, Harriet H. Webster, Seth Flaxman, Nick Andrews,  
927 Wes Hinsley, et al. 2022. “Comparative Analysis of the Risks of Hospitalisation and Death  
928 Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England:  
929 A Cohort Study.” *The Lancet* 399 (10332): 1303–12.
- 930 Office for National Statistics. 2023. “Results - Weekly Swab Positivity Updates from ONS.” Results -  
931 Weekly Swab Positivity Updates from ONS. 2023.  
932 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddisea  
933 ses/bulletins/coronaviruscovid19infectionsurveypilot/24march2023](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/24march2023).
- 934 Ogden, Nicholas H., Patricia Turgeon, Aamir Fazil, Julia Clark, Vanessa Gabriele-Rivet, Theresa Tam,  
935 and Victoria Ng. 2022. “Counterfactuals of Effects of Vaccination and Public Health Measures



- 936 on COVID-19 Cases in Canada: What Could Have Happened?” *Canada Communicable Disease*  
937 *Report = Relevé Des Maladies Transmissibles Au Canada* 48 (7–8): 292–302.
- 938 Otto, Sarah P., Troy Day, Julien Arino, Caroline Colijn, Jonathan Dushoff, Michael Li, Samir Mechai, et  
939 al. 2021. “The Origins and Potential Future of SARS-CoV-2 Variants of Concern in the Evolving  
940 COVID-19 Pandemic.” *Current Biology: CB* 31 (14): R918–29.
- 941 Our World in Data. 2023. “Our World in Data.” Daily COVID-19 Vaccine Doses Administered. 2023.  
942 <https://ourworldindata.org/grapher/daily-covid-19-vaccination-doses>.
- 943 Oved, Kfir, Liraz Olmer, Yonat Shemer-Avni, Tamar Wolf, Lia Supino-Rosin, George Prajgrod, Yotam  
944 Shenhar, et al. 2020. “Multi-Center Nationwide Comparison of Seven Serology Assays Reveals  
945 a SARS-CoV-2 Non-Responding Seronegative Subpopulation.” *EClinicalMedicine* 29  
946 (December): 100651.
- 947 Puhach, Olha, Kenneth Adea, Nicolas Hulo, Pascale Sattonnet, Camille Genecand, Anne Iten,  
948 Frédérique Jacquérior, et al. 2022. “Infectious Viral Load in Unvaccinated and Vaccinated  
949 Individuals Infected with Ancestral, Delta or Omicron SARS-CoV-2.” *Nature Medicine* 28 (7):  
950 1491–1500.
- 951 Scherer, Almut, and Angela McLean. 2002. “Mathematical Models of Vaccination.” *British Medical*  
952 *Bulletin* 62: 187–99.
- 953 Statistics Canada. 2023. “Population Estimates on July 1st, by Age and Sex.” Population Estimates on  
954 July 1st, by Age and Sex. 2023.  
955 <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1710000501>.
- 956 Talic, Stella, Shivangi Shah, Holly Wild, Danijela Gasevic, Ashika Maharaj, Zanfina Ademi, Xue Li, et  
957 al. 2021. “Effectiveness of Public Health Measures in Reducing the Incidence of Covid-19,  
958 SARS-CoV-2 Transmission, and Covid-19 Mortality: Systematic Review and Meta-Analysis.”  
959 *BMJ* 375 (November): e068302.
- 960 Tan, Sophia T., Ada T. Kwan, Isabel Rodríguez-Barraquer, Benjamin J. Singer, Hailey J. Park, Joseph  
961 A. Lewnard, David Sears, and Nathan C. Lo. 2023. “Infectiousness of SARS-CoV-2  
962 Breakthrough Infections and Reinfections during the Omicron Wave.” *Nature Medicine* 29 (2):  
963 358–65.
- 964 The Royal Society. 2023. “COVID-19: Examining the Effectiveness of Non-Pharmaceutical  
965 Interventions.” [https://royalsociety.org/-/media/policy/projects/impact-non-pharmaceutical-](https://royalsociety.org/-/media/policy/projects/impact-non-pharmaceutical-interventions-on-covid-19-transmission/the-royal-society-covid-19-examining-the-effectiveness-of-non-pharmaceutical-interventions-report.pdf)  
966 [interventions-on-covid-19-transmission/the-royal-society-covid-19-examining-the-effectiveness-](https://royalsociety.org/-/media/policy/projects/impact-non-pharmaceutical-interventions-on-covid-19-transmission/the-royal-society-covid-19-examining-the-effectiveness-of-non-pharmaceutical-interventions-report.pdf)  
967 [of-non-pharmaceutical-interventions-report.pdf](https://royalsociety.org/-/media/policy/projects/impact-non-pharmaceutical-interventions-on-covid-19-transmission/the-royal-society-covid-19-examining-the-effectiveness-of-non-pharmaceutical-interventions-report.pdf).
- 968 UKHSA. 2023. “COVID-19 Omicron Variant Infectious Period and Transmission from People with  
969 Asymptomatic Compared with Symptomatic Infection: A Rapid Review.” GOV-14430. {UK  
970 Health Security Agency}. [https://www.gov.uk/government/publications/covid-19-omicron-](https://www.gov.uk/government/publications/covid-19-omicron-variant-infectious-period-and-asymptomatic-and-symptomatic-transmission)  
971 [variant-infectious-period-and-asymptomatic-and-symptomatic-transmission](https://www.gov.uk/government/publications/covid-19-omicron-variant-infectious-period-and-asymptomatic-and-symptomatic-transmission).
- 972 VirusSeq. 2023. “Canadian VirusSeq Data Portal.” Canadian VirusSeq Data Portal. 2023.  
973 <https://virusseq-dataportal.ca/>.
- 974 Wei, Jia, Nicole Stoesser, Philippa C. Matthews, Daniel Ayoubkhani, Ruth Studley, Iain Bell, John I.  
975 Bell, et al. 2021. “Antibody Responses to SARS-CoV-2 Vaccines in 45,965 Adults from the  
976 General Population of the United Kingdom.” *Nature Microbiology* 6 (9): 1140–49.
- 977 Wichmann, Bruno, and Roberta Moreira Wichmann. 2023. “Big Data Evidence of the Impact of  
978 COVID-19 Hospitalizations on Mortality Rates of Non-COVID-19 Critically Ill Patients.”  
979 *Scientific Reports* 13 (1): 13613.
- 980 Xin, Hualei, Zhe Wang, Shuang Feng, Zhou Sun, Lele Yu, Benjamin J. Cowling, Qingxin Kong, and  
981 Peng Wu. 2023. “Transmission Dynamics of SARS-CoV-2 Omicron Variant Infections in  
982 Hangzhou, Zhejiang, China, January-February 2022.” *International Journal of Infectious*  
983 *Diseases: IJID: Official Publication of the International Society for Infectious Diseases* 126  
984 (January): 132–35.